Business
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial\nSAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.\n\n \n \n \n \n \n \n\n \nThe presentation, entitled \"Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer - A Phase 1 Clinical Trial\" will be presented by Dr. Pamela Garzone, Anixa's Chief Development Officer; and will discuss the clinical development of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.\n\"We are pleased to be presenting at the Ovarian Cancer National Conference,\" said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. \"We look forward to providing an overview of our Phase 1 ovarian cancer trial to an audience which is highly interested in new therapies to battle ovarian cancer.\"\nThe Ovarian Cancer National Conference is organized by the Ovarian Cancer Research Alliance (\"OCRA\"). OCRA is the leading organization in the world fighting ovarian cancer from all fronts while supporting women and their families. The organization has invested $100 million in ovarian cancer research, educated 95,000 medical professionals, and advocated for $200 million in government research and education funding.\nAbout Anixa Biosciences, Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on cli...